Aquinox Pharmaceuticals
Vancouver
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program for blood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $221.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2016)
- Ticker: nasdaq:AQXP
- Website: aqxpharma.com
- Phone: 604.629.9223
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aquinox-pharmaceuticals-179509 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.